Bildkälla: Stockfoto

Asarina Pharma: Two more to go - Redeye

Redeye deep-dives into the Tourette indication and includes it in our Sum of the Parts (SOTP) valuation. The inclusion of Tourette drives the increase in our Base Case. In this update, we also preview the upcoming results in Menstrual Migraine. Notably, both phase 2 studies in Tourette and Menstrual Migraine are funded.

Redeye deep-dives into the Tourette indication and includes it in our Sum of the Parts (SOTP) valuation. The inclusion of Tourette drives the increase in our Base Case. In this update, we also preview the upcoming results in Menstrual Migraine. Notably, both phase 2 studies in Tourette and Menstrual Migraine are funded.
Börsvärldens nyhetsbrev
ANNONSER